![Maj-Britt Kaltoft](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Maj-Britt Kaltoft
Corporate Officer/Principal en Statens Serum Institute .
Cargos activos de Maj-Britt Kaltoft
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Statens Serum Institute | Corporate Officer/Principal | 01/01/2017 | - |
Historial de carrera de Maj-Britt Kaltoft
Antiguos cargos conocidos de Maj-Britt Kaltoft.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SANUWAVE HEALTH, INC. | Director/Miembro de la Junta | 16/06/2017 | 28/06/2021 |
Independent Dir/Board Member | 16/06/2017 | 28/06/2021 | |
NOVO NORDISK A/S | Corporate Officer/Principal | 01/01/2011 | 01/01/2016 |
EffRx, Inc.
![]() EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Director de Operaciones | 01/11/2010 | 10/06/2011 |
Nycomed Hellas SA | Director/Miembro de la Junta | 01/01/2007 | 01/01/2007 |
H. LUNDBECK A/S | Corporate Officer/Principal | 01/01/2003 | 01/01/2003 |
Takeda A/S
![]() Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Corporate Officer/Principal | - | - |
EffRx Pharmaceuticals SA
![]() EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Director de Operaciones | 13/06/2011 | - |
Formación de Maj-Britt Kaltoft.
University of Copenhagen | Doctorate Degree |
Seattle University | Graduate Degree |
Estadísticas
Internacional
Dinamarca | 6 |
Estados Unidos | 4 |
Grecia | 2 |
Operativa
Corporate Officer/Principal | 4 |
Chief Operating Officer | 2 |
Graduate Degree | 2 |
Sectorial
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
NOVO NORDISK A/S | Health Technology |
H. LUNDBECK A/S | Health Technology |
SANUWAVE HEALTH, INC. | Health Technology |
Empresas privadas | 4 |
---|---|
EffRx, Inc.
![]() EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Health Technology |
Nycomed Hellas SA | |
EffRx Pharmaceuticals SA
![]() EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Health Technology |
Takeda A/S
![]() Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
- Bolsa de valores
- Insiders
- Maj-Britt Kaltoft
- Experiencia